Protocol Number; CINC280AJP01

Special drug use-results surveillance of Tabrecta Tablets (MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancer)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031200409

Enrollment

100

Registered

2021-03-11

Start date

2020-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
1.Number of patients with adverse reactions [ Time Frame: 1 year ] 2.Response rate [ Time Frame: 1 year ] 3.Overall survival rate [ Time Frame: 1 year ] 4.Progression-free survival (PFS) [ Time Frame: 1 year ]	—

Contacts

Public ContactNovartis Direct

Novartis Pharma. K.K.

sm.pms@novartis.com+81-120003293

Outcome results